Physician profile
Krystal Mitchell
NPI 1801391040
$5,173.23
in general payments reported to CMS, 2019-2025
26 companies · $856 in 2025
The $856 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $748 · 2020: $519 · 2021: $903 · 2022: $981 · 2023: $440 · 2024: $726 · 2025: $856.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,004 · Education: $16.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,004.34 |
| Education | $16.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $1,114.00 | 2019-2025 | Tremfya |
| Abbvie INC. | $738.23 | 2023-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $507.46 | 2019-2022 | |
| Janssen Biotech, INC. | $492.44 | 2019-2025 | Tremfya, Stelara, Simponi |
| Galderma Laboratories, L.P. | $297.68 | 2019-2021 | |
| Ucb, INC. | $297.04 | 2022-2025 | Bimzelx |
| Novartis Pharmaceuticals Corporation | $165.68 | 2022 | |
| Lilly USA, LLC | $164.47 | 2021-2025 | Ebglyss, Taltz |
| Arcutis Biotherapeutics, INC. | $160.75 | 2023-2025 | Zoryve |
| Epi Health, LLC | $135.24 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $125.00 | 2022 | |
| Biofrontera INC. | $125.00 | 2022 | |
| Stemline Therapeutics INC. | $125.00 | 2019 | |
| Amgen INC. | $119.85 | 2022 | |
| Almirall LLC | $105.81 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $99.99 | 2020 | |
| Sun Pharmaceutical Industries INC. | $83.39 | 2022 | |
| Vyne Pharmaceuticals INC. | $53.00 | 2020 | |
| Pfizer INC. | $46.78 | 2020-2021 | |
| Organogenesis INC. | $40.67 | 2023-2025 | Puraply, Puraply Wound Matrix |
| Incyte Corporation | $37.67 | 2025 | Opzelura |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.26 | 2024-2025 | Spevigo |
| Viiv Healthcare Company | $30.26 | 2025 | Apretude |
| Bioventus LLC | $25.93 | 2022 | |
| Paratek Pharmaceuticals, INC. | $24.70 | 2025 | Nuzyra |
| Genzyme Corporation | $19.93 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Krystal Mitchell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.